Despite the introduction of several new therapeutic options, a significant fraction of the patients with epilepsy continue to live with uncontrolled seizures. Although large no. of antiepileptic drug area available in the market, most of these agents have a limited spectrum of antiepileptic activity and all have certain negative properties that limit their utility and complicate patient management, so there is still a need for an ideal antiepileptic agent with properties like broad spectrum activity, rapid onset of action, least side effects, good oral bioavailability and low cost. Methodology: Albino rats weighing 150-200g, 6-8 weeks old of either sex, were used in the study. Rats were randomly allocated in to 9 groups each group consists of six. Group 1: control II, III: Riluzole 5, 10mg/kg respectively, IV, V, VI: Phenytoin 25, 50, 100mg/kg respectively. VII, VIII, IX: Riluzole 10mg/kg in combination with Phenytoin 25, 50, 100mg/kg respectively. Drugs were administered to all groups orally by orogastric tube, as per the study subgroups. 30miutes later the rats were subjected to an electric shock by using an electro convulsiometer: Presence or absence of hind limb extensor, duration of Hind limb tonic extensor (HLTE) phase & duration of clonus in sec. Result: Riluzole at both dosages of 5 & 10mg/kg did not modify the MES induced convulsions. Phenytoin at a dose of 25mg/kg & 50mg/kg could not abolish the hind limb extension. However phenytoin at 100mg/kg produced 100% abolition of Hind Limb Extension. Phenytoin at 25mg/kg & 50mg/kg dosage insignificantly reduced the duration of Hind Limb Extensions without any effect on clonic phase. At the same time phenytoin at 100mg/kg significantly increased the duration of clonus from 9, 8 to 18, 3 seconds, but interestingly when Riluzole 10mg/kg was combined with
Phenytoin 50mg/kg, the Hind Limb Extension was abolished in 50% animals. When the dose of Phenytoin was further increased to 100mg it produced 100% protection by abolishing Hind Limb Extension. Similar effects were produced when Riluzole was combined with 100mg of Phenytoin. Conclusion: Riluzole alone was found to be ineffective against MES induced seizures, however it was found to enhance the antiepileptic effect of phenytoin against MES induced seizures.
Fisher RS, Acevedo C, Arzimanoglou A, Bogaz A, Cross JH, Elger CE, etal., A practical clinical defination of epilepsy, ILAE Offical Report, Epilepsia 2014;55 (4);475-82
Gopi G, Jayasri P, Elumalali A. Antiepileptic effect of MALACHRA CAPITATA L. On maximal electro shock (MES) and Pentylenetetrazole (PTZ) induced seizures. International journals of Pharmacology and Toxicology. Year,2(2):104-108
Bharucha NE, Epidemiology of epilepsy in india. Epilepsia 2003;44(1):9-11
White HS, Preclinical development of antiepileptic drugs;Past,present and future directions. Epilepsia 2003;44(7):2-8
La Roche SM, Helmers SL. The new antiepileptic drug. JAMA 2004;291(5):605.
Raymond Dingledine and Chris J McBain Glutamate & asparate are the major excitatory transmitters in the brain, Basic Neurochemistry: Molecular, Cellular & Medical Aspects, 6th edition (1999).
Olsen RW, Wamsley JK, Lee RJ, Lomax P, Benzodiazepine / Barbiturate / GABA receptor chloride ionophore complex is a genetic model of generalized epilepsy . Adv Neurol 1986;44:365-78.
Riluzole enhances the anti-siezure action of conventional anti-epileptic drugs against pentetrazole induced convulsion in mice. Pol. J Pharmacol, 2004;56(2):187-193
James O, McNamara, Pharmacotherapy of the Epilepsies in : Laurence L, Bruton, Bruce A, Chabner Bjorn C, Knollmann, editors, Goodman & Gilman's The Pharmacological basis of therapeutic. 12th ED. New york: McGraw Hill ; 2011,p. 124-42 .
Satoskar RS, Bhendarkar SD, RegeNN, pharmacology and pharmacotherapeutic. 22nd ED, Mumbai, India : Popular Prakashan: 2011,p.124 -42
Khanna N, Balla S, Verma V, Sharma KK. Modulary effect of nifedipine and nimodipine in experimental convulsion. Indian journal of Pharmacology 2000 ;32: 347-352
Ashish P , Anovadiya , Jayesh J, Sanmukhani, Vishal K, Vadgama, C.B. Tripathi Evalution of antiepileptic and memory retention action of curcumi per se and in combination with antiepileptic drugs. Asian J Pharmacology 2013;6(S2): 145-148
Castel-Branco MM, Alves GL, Figue Falcao AC, Caramona MM. The electroshock seizure (mes) moderate preclinical assessment of potential antiepileptic drugs. Method Find Each Pharmcol 2009,31(2):101-106
Ramanand J Patil, Patel SB, Abhijeet, Madhukar Gaikwad. Evalution of anticonvulsant activity of ameprazole comparison with phenytoin in albino mice INTERNATIONAL JOURNAL OF EXPERIMENT PHARMACOLOGY.2015;5(1):18-23.
Kretschmer BD, Kratzer U, Schmiat WJ; Riluzole, a glutamate release inhibitor and motor behavior, Naunyn Schmiedebergs Arch Pharmacol, 1998,358,181-190
Mantz J, Laudenbach V, Lechamy JB, Henzel D, Desmonts JM, Riluzole, a novel antiglutamate blocks GABA uptake by striatal synaptosomes Eur J Pharmacol,1994,257,R7-R8.
Samuel D, Blin O, Dusticier N, Nieoullon A: Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical marker in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake. Fundam Clin Pharmacol.1992;6(4-5):177-84
Mary V, Wahi F, Stutzman JM: Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers od glutamatergic neurotransmission. Neurosci Lett, 1995, 201, 92-96.
Malgouris C, Daniel M, Doble A: Neuroprotective effect of riluzole on N-methyl-D-asparate- or veratridine- induced neurotoxicity in rat hippocampal slices, Neurosci Lett, 1994,177,95-99.
Mizoule J, Meidrum B, Mazadier M, Croucher M, Ollat C, Uzan A, Legrand JJ et al: 2-Amino-6-trifluoromethoxy - benzothiazole, a possible antagonist of excitatory amino acid neurotransmission, I, Anticonvulsant properties. Neuropharmacology,1985,24,767-773.
De Sarro G, Siniscalchi A, Ferreri G, Gallelli L, De Sarro A: NMDA and AMPA/Kainate receptors are involved in the Anticonvulsant activity of riluzole in DBA2/mice. Eur J Phamacol, 2000, 408,25-34.
Parsons CG, Danysz W, Quack G: Glutamate in CNS disorders as target for drug development: an update. Drugs News Perspect, 1998,11,523-569.
Czuczwar SJ, Turski WA, Kleinrok Z: interaction of calcium channel blockers and excitatory amino acid antagonist with conventional antiepileptic drugs. CNS Drug Rev. 1996,2, 452-467.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.